Treat alcohol and opioid concurrent withdrawal with buprenorphine: Study

A study of patients admitted to an acute psychiatric unit for concurrent alcohol and opioid withdrawal found that those initiated on buprenorphine within 24 hours had the lowest rate of patient‐directed discharge (PDD), otherwise known as leaving treatment against medical advice. The study highlighted the importance of treating both alcohol use disorder and opioid use disorder concurrently. Despite the well‐established evidence that treating each disorder is effective, there is limited research on concurrently treating both, according to the authors of “Impact of Time to Buprenorphine Initiation on Patient‐Directed Discharge in Concurrent Alcohol and Opioid Withdrawal,” published in the AMERSA publication Substance Use & Addiction Journal online August 14. Treating patients who are going through both alcohol and opioid withdrawal with buprenorphine has benefits for patients and facilities, concluded the research, led by Sean Blaeser, Pharm.D., and colleagues. For the article, the researchers conducted a single‐center retrospective study of patients admitted to the acute psychiatry unit from January 2019 through September 2023 who were at risk for concurrent alcohol and opioid withdrawal. The 322 patients were divided into four cohorts depending on time from admission to buprenorphine administration: 0 to 24 hours (n = 85), 24 to 72 hours (n = 44), greater than 72 hours (n = 16), and those who did not receive buprenorphine (n = 187). Of all admissions meeting inclusion criteria, 43.7% (n = 145) received buprenorphine. Those who did not receive buprenorphine had higher rates of PDD than those who did not (15.5% [n = 29] vs. 6.9% [n = 10]). They also had higher PDD rates than those who initiated buprenorphine between 24 and 72 hours versus 0 to 24 hours of admission (11.4% [n = 5] vs. 5.9% [n = 5]). Absence of buprenorphine initiation also resulted in higher inpatient readmission rates at both 30 (25.1% [n = 47] vs. 11.0% [n = 16]) and 90 days (46% [n = 86] vs. 24.1% [n = 35]).

Authors

Publication Details

Journal
Alcoholism & Drug Abuse Weekly
Published
2026-09-11
DOI
https://doi.org/10.1002/adaw.35044
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Treat alcohol and opioid concurrent withdrawal with buprenorphine: Study

Alison Knopf
Alcoholism & Drug Abuse Weekly
Opioid Use Disorder Treatment
article

Treat alcohol and opioid concurrent withdrawal with buprenorphine: Study

Alison Knopf
article en

Abstract

A study of patients admitted to an acute psychiatric unit for concurrent alcohol and opioid withdrawal found that those initiated on buprenorphine within 24 hours had the lowest rate of patient‐directed discharge (PDD), otherwise known as leaving treatment against medical advice. The study highlighted the importance of treating both alcohol use disorder and opioid use disorder concurrently. Despite the well‐established evidence that treating each disorder is effective, there is limited research on concurrently treating both, according to the authors of “Impact of Time to Buprenorphine Initiation on Patient‐Directed Discharge in Concurrent Alcohol and Opioid Withdrawal,” published in the AMERSA publication Substance Use & Addiction Journal online August 14. Treating patients who are going through both alcohol and opioid withdrawal with buprenorphine has benefits for patients and facilities, concluded the research, led by Sean Blaeser, Pharm.D., and colleagues. For the article, the researchers conducted a single‐center retrospective study of patients admitted to the acute psychiatry unit from January 2019 through September 2023 who were at risk for concurrent alcohol and opioid withdrawal. The 322 patients were divided into four cohorts depending on time from admission to buprenorphine administration: 0 to 24 hours (n = 85), 24 to 72 hours (n = 44), greater than 72 hours (n = 16), and those who did not receive buprenorphine (n = 187). Of all admissions meeting inclusion criteria, 43.7% (n = 145) received buprenorphine. Those who did not receive buprenorphine had higher rates of PDD than those who did not (15.5% [n = 29] vs. 6.9% [n = 10]). They also had higher PDD rates than those who initiated buprenorphine between 24 and 72 hours versus 0 to 24 hours of admission (11.4% [n = 5] vs. 5.9% [n = 5]). Absence of buprenorphine initiation also resulted in higher inpatient readmission rates at both 30 (25.1% [n = 47] vs. 11.0% [n = 16]) and 90 days (46% [n = 86] vs. 24.1% [n = 35]).

Alcoholism & Drug Abuse WeeklyVol. 38(35)
Good health and well-being
Openalex Percentile: Top 9%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.